We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018

Published: July 2018
Pages: 83
Code: 6AF5F032D357726CDDE81CCA9514F4BB
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,000.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.
When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastro esophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 5, 3 and 1 respectively.
Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
  • - The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Companies Mentioned

Ahn-Gook Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development
  • Ahn-Gook Pharmaceutical Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Daewoong Pharmaceutical Co Ltd
  • Eisai Co Ltd
  • Ilyang Pharmaceutical Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Sun Pharma Advanced Research Company Ltd
  • Takeda Pharmaceutical Co Ltd
  • Yooyoung Pharm Co Ltd
  • Yuyu Pharma Inc
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles
  • (esomeprazole + sodium bicarbonate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • azeloprazole sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ceclazepide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CJ-30065 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • colesevelam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dexlansoprazole DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DWP-14012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • esomeprazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • G-17DT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ilaprazole DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JP-1366 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naronapride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • netazepide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pantoprazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pantoprazole DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00000774 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 for Peptic Ulcers and Reflux Esophagitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tegoprazan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vonoprazan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • X-842 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YY-DXR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
  • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
  • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
  • May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018
  • Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
  • Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease
  • Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
  • Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
  • Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
  • Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease
  • Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
  • Jan 27, 2016: FDA Approves Takeda’s Dexilant SoluTab (dexlansoprazole)
  • Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
  • Feb 26, 2015: TAKECAB Now Available for the Treatment of Acid-related Diseases in Japan
  • Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastro esophageal Reflux Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H2 2018
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H2 2018 (Contd..1), H2 2018
  • List of Figures
  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

Keywords
;